Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Non-Current Liabilities (2018 - 2023)

China Pharma Holdings' Total Non-Current Liabilities history spans 11 years, with the latest figure at $10.5 million for Q1 2023.

  • For Q1 2023, Total Non-Current Liabilities changed N/A year-over-year to $10.5 million; the TTM value through Mar 2023 reached $10.5 million, changed N/A, while the annual FY2022 figure was $11.1 million, 24.71% down from the prior year.
  • Total Non-Current Liabilities reached $10.5 million in Q1 2023 per CPHI's latest filing, down from $11.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $14.7 million in Q4 2021 to a low of $9.6 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $11.0 million, with a median of $10.5 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: surged 42.28% in 2021, then dropped 24.71% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $10.6 million in 2019, then decreased by 2.18% to $10.4 million in 2020, then soared by 42.28% to $14.7 million in 2021, then decreased by 24.71% to $11.1 million in 2022, then dropped by 5.3% to $10.5 million in 2023.
  • Per Business Quant, the three most recent readings for CPHI's Total Non-Current Liabilities are $10.5 million (Q1 2023), $11.1 million (Q4 2022), and $14.7 million (Q4 2021).